Text Size

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00057954
First received: April 7, 2003
Last updated: February 11, 2013
Last verified: February 2013
History of Changes
Results First Received: January 7, 2013  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Lymphoma
Interventions: Procedure: Extracorporeal Photopheresis
Drug: Pentostatin
Radiation: Total body irradiation (TBI)
Procedure: Allogeneic bone marrow transplantation
Drug: Cyclosporin (CSA)
Drug: Mycophenolate mofetil (MMF)
Drug: Methotrexate (MTX)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from ECOG member institutions between June 1, 2005 and October 10, 2007.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Transplant Reduced toxicity conditioning regimen followed by allogeneic (sibling or unrelated) transplant.

Participant Flow:   Overall Study
    Transplant  
STARTED     6  
COMPLETED     4  
NOT COMPLETED     2  
Death                 1  
Disease progression                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Transplant Reduced toxicity conditioning regimen followed by allogeneic sibling or unrelated transplant.

Baseline Measures
    Transplant  
Number of Participants  
[units: participants]
 		  6  
Age  
[units: years]
Median ( Full Range ) 		  47  
  ( 21 to 60 )  
Gender  
[units: participants]
 		 
Female     2  
Male     4  
Region of Enrollment  
[units: participants]
 		 
United States     6  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Proportion of Participants With Successful Engraftment   [ Time Frame: Assessed daily during inpatient stay ]
  Show Outcome Measure 1

2.  Secondary:   100-day Overall Survival   [ Time Frame: Assessed at least twice a week for the first 60 days and weekly until day 100. ]
  Show Outcome Measure 2

3.  Secondary:   Progression-free Survival   [ Time Frame: Assessed day 100 post transplant and every 3 months during year 1, every 6 months during years 2-3, then every 12 months during years 4-5 or through diagnosis of disease progression ]
  Show Outcome Measure 3


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Study Statistician
Organization: ECOG Statistical Office
phone: 617-632-3012


No publications provided


Responsible Party: Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier: NCT00057954     History of Changes
Other Study ID Numbers: CDR0000285659, U10CA021115, E1402
Study First Received: April 7, 2003
Results First Received: January 7, 2013
Last Updated: February 11, 2013
Health Authority: United States: Federal Government